Evidence map›Paper›PMID 38567507›Full record

ArticleCirculation. Cardiovascular quality and outcomes2024

Impact of Local Tailoring on Acute Stroke Care in 21 Disparate Emergency Departments: A Prospective Stepped Wedge Type III Hybrid Effectiveness-Implementation Study.

Kathleen E McKee, Andrew J Knighton, Kristy Veale, Julie Martinez, Cory McCann, Jonathan W Anderson, Doug Wolfe, Robert Blackburn, Marilyn McKasson, Tyler Bardsley and 5 more

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Circulation. Cardiovascular quality and outcomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Israel should build capacity in implementation science.Israel journal of health policy research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Kathleen E McKee *Neurosciences Clinical Program (K.E.M., K.V., J.M., C.M.C., M.M.K., R.H., H.A.P.), Intermountain Health, Salt Lake City, UT.
Andrew J Knighton *Healthcare Delivery Institute (A.J.K., D.W., R.S.), Enterprise Analytics (J.W.A.), Intermountain Health, Salt Lake City, UT.ORCID 0000-0002-8276-0454
Kristy VealeNeurosciences Clinical Program (K.E.M., K.V., J.M., C.M.C., M.M.K., R.H., H.A.P.), Intermountain Health, Salt Lake City, UT.
Julie MartinezNeurosciences Clinical Program (K.E.M., K.V., J.M., C.M.C., M.M.K., R.H., H.A.P.), Intermountain Health, Salt Lake City, UT.ORCID 0000-0001-9139-6693
Cory McCannNeurosciences Clinical Program (K.E.M., K.V., J.M., C.M.C., M.M.K., R.H., H.A.P.), Intermountain Health, Salt Lake City, UT.
Jonathan W AndersonNeurosciences Clinical Program (K.E.M., K.V., J.M., C.M.C., M.M.K., R.H., H.A.P.), Intermountain Health, Salt Lake City, UT.
Doug WolfeHealthcare Delivery Institute (A.J.K., D.W., R.S.), Enterprise Analytics (J.W.A.), Intermountain Health, Salt Lake City, UT.
Robert BlackburnContinuous Improvement (R.B.), Intermountain Health, Salt Lake City, UT.
Marilyn McKassonNeurosciences Clinical Program (K.E.M., K.V., J.M., C.M.C., M.M.K., R.H., H.A.P.), Intermountain Health, Salt Lake City, UT.
Tyler BardsleyDivision of Biostatistics, School of Medicine (T.B., B.O.-A., T.H.G.), University of Utah, Salt Lake City.
Blessing Ofori-AttaDivision of Biostatistics, School of Medicine (T.B., B.O.-A., T.H.G.), University of Utah, Salt Lake City.ORCID 0009-0004-4332-3974
Tom H GreeneDivision of Biostatistics, School of Medicine (T.B., B.O.-A., T.H.G.), University of Utah, Salt Lake City.
Robert HoeschNeurosciences Clinical Program (K.E.M., K.V., J.M., C.M.C., M.M.K., R.H., H.A.P.), Intermountain Health, Salt Lake City, UT.
H Adrian PüttgenNeurosciences Clinical Program (K.E.M., K.V., J.M., C.M.C., M.M.K., R.H., H.A.P.), Intermountain Health, Salt Lake City, UT.ORCID 0000-0003-4016-6825
Rajendu SrivastavaHealthcare Delivery Institute (A.J.K., D.W., R.S.), Enterprise Analytics (J.W.A.), Intermountain Health, Salt Lake City, UT.ORCID 0000-0003-0649-6222
Intermountain Healthcare · USUniversity of Utah · US

Funding

CTSA UM1 Program at University of UtahUM1TR004409 · NCATS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI RACHEL HESS, Jennifer Juhl Majersik · 2023 to 2026
$21.9M
Vascular Health and Risk Factors in Children with Down SyndromeKL2TR002539 · NCATS · UNIVERSITY OF UTAH · PI MURTAUGH, MAUREEN A, NYGAARD, INGRID E · 2018 to 2022
$4.3M
NCATS NIH HHS KL2 TR002539NCATS NIH HHS UM1 TR004409
6 · The paper itself

Abstract

backgroundFaster delivery of tPA (tissue-type plasminogen activator) results in better health outcomes for eligible patients with stroke. Standardization of stroke protocols in emergency departments (EDs) has been difficult, especially in nonstroke centers. We measured the effectiveness of a centrally led implementation strategy with local site tailoring to sustain adherence to an acute stroke protocol to improve door-to-needle (DTN) times across disparate EDs in a multihospital health system.

methodsProspective, type III hybrid effectiveness-implementation cohort study measuring performance at 21 EDs in Utah and Idaho (stroke centers [4]/nonstroke centers [17]) from January 2018 to February 2020 using a nonrandomized stepped-wedge design, monthly repeated site measures and multilevel hierarchical modeling. Each site received the implementation strategies in 1 of 6 steps providing control and intervention data. Co-primary outcomes were percentage of DTN times ≤60 minutes and median DTN time. Secondary outcomes included percentage of door-to-activation of neurological consult times ≤10 minutes and clinical effectiveness outcomes. Results were stratified between stroke and nonstroke centers.

resultsA total of 855 474 ED patient encounters occurred with 5325 code stroke activations (median age, 69 [IQR, 56-79] years; 51.8% female patients]. Percentage of door-to-activation times ≤10 minutes increased from 47.5% to 59.9% (adjusted odds ratio, 1.93 [95% CI, 1.40-2.67]). A total of 615 patients received tPA of ≤3 hours from symptom onset (median age, 71 [IQR, 58-80] years; 49.6% female patients). The percentage of DTN times ≤60 minutes increased from 72.5% to 86.1% (adjusted odds ratio, 3.38, [95% CI, 1.47-7.78]; stroke centers (77.4%-90.0%); nonstroke centers [59.3%-72.1%]). Median DTN time declined from 46 to 38 minutes (adjusted median difference, -9.68 [95% CI, -17.17 to -2.20]; stroke centers [41-35 minutes]; nonstroke centers [55-52 minutes]). No differences were observed in clinical effectiveness outcomes.

conclusionsA centrally led implementation strategy with local site tailoring led to faster delivery of tPA across disparate EDs in a multihospital system with no change in clinical effectiveness outcomes including rates of complication. Disparities in performance persisted between stroke and nonstroke centers.

Indexed as

Emergency Service, HospitalFibrinolytic AgentsStrokeThrombolytic TherapyTime-to-TreatmentTissue Plasminogen ActivatorAgedAged, 80 and overFemaleGuideline AdherenceHealthcare DisparitiesHumansMaleMiddle AgedOutcome and Process Assessment, Health CareProspective StudiesFibrinolytic AgentsTissue Plasminogen Activatordelivery of health carehospital emergency servicesimplementation sciencequality improvementrural hospitalsstroketissue plasminogen activator

Identifiers

PMID38567507
PMCPMC11108744
OpenAlexW4393858549

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.